dc.contributor.author | Akbaş M,Koyuncu FM,Ülkümen BA,Taneli F,Özdemir H | |
dc.date.accessioned | 2023-03-02T11:25:41Z | |
dc.date.available | 2023-03-02T11:25:41Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12481/16269 | |
dc.description.abstract | Objective: Fetal hydronephrosis (FH) is the most common fetal renal pathology encountered in daily obstetric practice. Urinary and serum carbohydrate antigen 19-9 (CA 19-9) concentrations are elevated in obstructive renal pathologies. Our aim was to assess maternal urinary and serum CA 19-9 concentrations in pregnancies with FH and compare results with controls. Material and Methods: Twenty pregnancies with severe FH, 20 pregnancies with mild-moderate FH, and 20 healthy singleton pregnancies were included in this descriptive, case-control study. The diagnosis and classification of FH was based on the anterioposterior diameter of fetal renal pelvis. Maternal urinary and serum CA 19-9 concentrations were measured and compared between groups. Results: Severe FH cases had significantly higher maternal urinary CA 19-9 concentrations compared to controls (median: 75 vs 24 U/mL; respectively; p=0.014). Concentrations of CA 19-9 did not differ between the mild-moderate FH group and control group. No statistically significant difference was found between the groups with respect to maternal serum CA 19-9 concentrations. Conclusion: Our results show that maternal urinary CA 19-9 concentration is significantly higher in pregnancies with severe FH. However, no difference was detected in serum CA 19-9 concentrations between pregnancies with severe FH, mild-moderate FH and controls. If the mechanisms of transplacental passage and maternal urinary excretion are clarified, maternal urinary CA 19-9 may be a potential marker for indicating fetal kidney damage. © 2020 by the Turkish-German Gynecological Education and Research Foundation. | |
dc.title | Can maternal urinary and serum carbohydrate antigen 19-9 concentrations be utilized in the diagnosis of fetal hydronephrosis? | |
dc.identifier.DOI-ID | 10.4274/jtgga.galenos.2019.2019.0101 | |
dc.identifier.volume | 21 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 41 | |
dc.identifier.endpage | 45 | |
dc.identifier.issn/e-issn | 1309-0399 | |